CLINUVEL PHARMACEUTICALS LTD (Seite 2167)
eröffnet am 24.04.07 13:00:35 von
neuester Beitrag 29.05.24 19:45:45 von
neuester Beitrag 29.05.24 19:45:45 von
Beiträge: 22.294
ID: 1.126.403
ID: 1.126.403
Aufrufe heute: 4
Gesamt: 4.030.016
Gesamt: 4.030.016
Aktive User: 0
ISIN: AU000000CUV3 · WKN: A0JEGY
9,4375
EUR
0,00 %
0,0000 EUR
Letzter Kurs 00:33:56 Lang & Schwarz
Neuigkeiten
| TitelBeiträge |
|---|
28.03.24 · globenewswire  |
07.03.24 · EQS Group AG |
05.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0450 | +14.021,62 | |
| 4,9600 | +41,71 | |
| 1,3000 | +26,21 | |
| 1,6700 | +25,56 | |
| 2,9350 | +22,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,9300 | -17,16 | |
| 2,1200 | -18,46 | |
| 9,6000 | -18,64 | |
| 1,4600 | -24,56 | |
| 1,7000 | -31,17 |
Beitrag zu dieser Diskussion schreiben
Feedback
was ist los? Absturz um 10% !! Gibts Neuigkeiten?
Antwort auf Beitrag Nr.: 38.629.984 von Karl79 am 24.12.09 13:43:11 früher war auch mehr lametta
Message from the CEO Dr. J. Christus v.Bethlehem:
Also Kinder, ich bin jetzt im Urlaub.
Aller Vorrausicht nach bin ich bis Weihnachten wieder da, aber die Vorbereitungen
darauf sollten natürlich jetzt schon loslaufen.
Also Kinder, ich bin jetzt im Urlaub.
Aller Vorrausicht nach bin ich bis Weihnachten wieder da, aber die Vorbereitungen
darauf sollten natürlich jetzt schon loslaufen.
FN Arena Broker Call Headlines - 23 Dec 2009
23/12/2009 11:15:02 AM
(CUV.AX
CLINUVEL PHRMCTL23 December,200923/12/2009 20:01 Sydney, Australia.
Price Change % Change
0.270 +0 +0%
Company overview
Real-time quote
CUV.AX , 0.270, +0, +0%) - CLINUVEL PHARMACEUTICALS LIMITED
RBS Australia rates (CUV.AX
CLINUVEL PHRMCTL23 December,200923/12/2009 20:01 Sydney, Australia.
Price Change % Change
0.270 +0 +0%
Company overview
Real-time quote
CUV.AX , 0.270, +0, +0%) as Buy - The broker notes two Phase III clinical trials by the company have delivered significant results and it suggests if further good results can be achieved it should support registration applications. This reinforces the broker's positive view on the stock and so it retains its Buy rating with an unchanged $0.78 price target.
Quelle: http://money.ninemsn.com.au/article.aspx?id=987034
23/12/2009 11:15:02 AM
(CUV.AX
CLINUVEL PHRMCTL23 December,200923/12/2009 20:01 Sydney, Australia.
Price Change % Change
0.270 +0 +0%
Company overview
Real-time quote
CUV.AX , 0.270, +0, +0%) - CLINUVEL PHARMACEUTICALS LIMITED
RBS Australia rates (CUV.AX
CLINUVEL PHRMCTL23 December,200923/12/2009 20:01 Sydney, Australia.
Price Change % Change
0.270 +0 +0%
Company overview
Real-time quote
CUV.AX , 0.270, +0, +0%) as Buy - The broker notes two Phase III clinical trials by the company have delivered significant results and it suggests if further good results can be achieved it should support registration applications. This reinforces the broker's positive view on the stock and so it retains its Buy rating with an unchanged $0.78 price target.
Quelle: http://money.ninemsn.com.au/article.aspx?id=987034
Trial results are promising: ClinuvelTREVOR CHAPPELL
December 21, 2009
Ads by Google
Melanotan 2 from the UK
48 hour shipping by RoyalMail100%Pure No customs Tan injections
www.MT2.org.uk
AAP
Biotech Clinuvel Pharmaceuticals Ltd says its phase III trial of its photoprotective drug, afamelanotide, in Europe and Australia has achieved promising results over a four-month period.
Clinuvel is testing the drug to treat patients suffering from erythropoietic protoporphyria (EPP), a genetic disorder that causes intolerance in the skin to ultraviolet radiation (UV) and light.
People with EPP suffer painful symptoms from exposure to sunlight and UV, such as severe burning pain, and in extreme cases can even be affected by the light from computer screens indoors.
The condition prevents people undertaking activities outdoors and reduces the quality of their life.
Clinuvel said interim analysis of data from the first four months of treatment in the 12-month trial involving around 100 patients, showed an overall reduction in the average number of phototoxic reactions.
"Although the analysis of quality-of-life data is not yet complete, all eight physicians involved in this trial reported a dramatic improvement in the patients' ability to engage in outdoor activities," Clinuvel said on Monday.
"Safety reports from all academic centres are excellent to date."
Data will be fully analysed once the trial is completed by the end of December 2009. The company hopes to report final phase III results in February.
Clinuvel subsequently hopes to submit an application to register the drug in Europe.
The company is awaiting approval from the United States Food and Drug Administration to start phase III trials in the US.
Clinuvel managing director Dr Philippe Wolgen said patients had been responding well to afamelanotide during the trial, with 97 of the 101 patients requesting the drug after completion of the trial.
"So we as a company decided we would give the drug on a compassionate basis for another 12 months free."
"From a commercial point of view it's a very expensive exercise, but from a humane and scientific view, it's probably the best news that you can have.
"Because if there's already demand before you enter the commercial phase, you know you have an effective drug."
Dr Wolgen said about 300 people suffer from EPP in Australia, and about 4,000 to 6,000 around the world have the condition.
Shares in Clinuvel were 1.5 cents higher at 29 cents at 1546 AEDT on Monday.
Quelle: http://news.smh.com.au/breaking-news-business/trial-results-…
December 21, 2009
Ads by Google
Melanotan 2 from the UK
48 hour shipping by RoyalMail100%Pure No customs Tan injections
www.MT2.org.uk
AAP
Biotech Clinuvel Pharmaceuticals Ltd says its phase III trial of its photoprotective drug, afamelanotide, in Europe and Australia has achieved promising results over a four-month period.
Clinuvel is testing the drug to treat patients suffering from erythropoietic protoporphyria (EPP), a genetic disorder that causes intolerance in the skin to ultraviolet radiation (UV) and light.
People with EPP suffer painful symptoms from exposure to sunlight and UV, such as severe burning pain, and in extreme cases can even be affected by the light from computer screens indoors.
The condition prevents people undertaking activities outdoors and reduces the quality of their life.
Clinuvel said interim analysis of data from the first four months of treatment in the 12-month trial involving around 100 patients, showed an overall reduction in the average number of phototoxic reactions.
"Although the analysis of quality-of-life data is not yet complete, all eight physicians involved in this trial reported a dramatic improvement in the patients' ability to engage in outdoor activities," Clinuvel said on Monday.
"Safety reports from all academic centres are excellent to date."
Data will be fully analysed once the trial is completed by the end of December 2009. The company hopes to report final phase III results in February.
Clinuvel subsequently hopes to submit an application to register the drug in Europe.
The company is awaiting approval from the United States Food and Drug Administration to start phase III trials in the US.
Clinuvel managing director Dr Philippe Wolgen said patients had been responding well to afamelanotide during the trial, with 97 of the 101 patients requesting the drug after completion of the trial.
"So we as a company decided we would give the drug on a compassionate basis for another 12 months free."
"From a commercial point of view it's a very expensive exercise, but from a humane and scientific view, it's probably the best news that you can have.
"Because if there's already demand before you enter the commercial phase, you know you have an effective drug."
Dr Wolgen said about 300 people suffer from EPP in Australia, and about 4,000 to 6,000 around the world have the condition.
Shares in Clinuvel were 1.5 cents higher at 29 cents at 1546 AEDT on Monday.
Quelle: http://news.smh.com.au/breaking-news-business/trial-results-…
Trading Spotlight
Antwort auf Beitrag Nr.: 38.617.670 von TinoTeletabbi am 22.12.09 15:22:58OMG, SORRY SORRY, ich dachte das war der Novelos thread...!!! Ignore my former comment!
Wahrscheinlich ein System Fehler sollte 1,18 sein LOL
71k zu 0,18 EUR auf Xstra?! 
Was`n da los?!
Was`n da los?!
...im Down-Under Thread diskutiert man gerade die negativ-Interpretation der Presse auf Wörter wie z.B. vorbeugende-Sonnerbrand-Spritze.
Das abdriften in die Sparte "kosmetische Abteilung" könnte gefährliche Auswirkungen auf die geplanten FDA-Zulassung haben.
Das abdriften in die Sparte "kosmetische Abteilung" könnte gefährliche Auswirkungen auf die geplanten FDA-Zulassung haben.
Durchsuchen
07.03.24 · EQS Group AG · Clinuvel Pharmaceuticals |
06.01.24 · wallstreetONLINE NewsUpdate · Evotec |
06.01.24 · wallstreetONLINE Redaktion · Evotec |
04.10.23 · wO Chartvergleich · Bayer |
20.09.23 · wO Chartvergleich · Borussia Dortmund |